Revisiting ISO 10993-5 In Vitro Cytotoxicity Standard Tests for Evaluation of Extracellular Matrix-Based...

Area of Science:

• Biomaterials Science
• Toxicology
• Cell Biology

Background:

• Cytotoxicity testing is crucial for preclinical evaluation of biomaterials and medical devices.
• Current ISO 10993-5 standard relies on metabolic assays and colony formation, which can lack precision and cause discrepancies.
• Extracellular matrix (ECM)-based biomaterials require robust in vitro cytotoxicity assessment.

Purpose of the Study:

• To systematically evaluate ISO 10993-5 recommended assays for ECM-based products.
• To assess the impact of variables like cell type, contact mode, and media components on assay outcomes.
• To identify limitations of current methods and support development of more accurate tests.

Main Methods:

• Evaluation of four standard metabolic assays (MTT, XTT) for in vitro cytotoxicity.
• Assessment of cell viability (live/dead staining), attachment (actin cytoskeleton), proliferation (Ki67), and apoptosis (annexin V).
• Comparison of results across different cell types (L929, human primary dermal fibroblasts), contact modes, and serum conditions.

Main Results:

• All standard assays indicated non-cytotoxicity, but metabolic activity varied significantly with assay conditions.
• Increased metabolic activity under serum-free conditions did not correlate with cell viability or attachment.
• Annexin V staining for apoptosis was only detected in human primary dermal fibroblasts, suggesting L929 cells are less reliable for this endpoint.

Conclusions:

• Standard metabolic assays in ISO 10993-5 may not accurately reflect cell function and can produce misleading results.
• Complementary assays assessing cell membrane integrity, proliferation, and apoptosis are essential for a comprehensive evaluation.
• Findings provide a reference for refining cytotoxicity testing protocols and guiding future ISO 10993-5 revisions for biomaterials.